425: Cyclacel Pharmaceuticals Amends Acquisition Terms for FITTERS Subsidiary, Adding $1 Million Cash Payment and Extending Deadline

Cyclacel Pharmaceuticals, Inc. has amended its agreement to acquire FITTERS Sdn. Bhd., adding a $1 million cash payment to the consideration and extending the transaction's final closing date to September 30, 2025, citing a decline in Cyclacel's valuation.

Summary

• Cyclacel Pharmaceuticals, Inc. (Cyclacel) entered into Amendment No. 1 to its Exchange Agreement with FITTERS Diversified Berhad (Fitters Parent) and FITTERS Sdn. Bhd. (Fitters Sub) on July 7, 2025.
• The original agreement, dated May 6, 2025, involved Cyclacel acquiring 100% of Fitters Sub in exchange for 19.99% of Cyclacel's common stock.
• The amendment introduces an additional consideration: Cyclacel will pay USD $1,000,000, or a mutually agreed upon amount, to Fitters Parent at closing.
• This cash payment was added because the parties agreed that Cyclacel's valuation had declined since the initial agreement's execution.
• The Final Date for the transaction has been extended from an unspecified prior date to September 30, 2025.
• The transaction is subject to approval from Cyclacel stockholders and Fitters Parent.
• The Boards of Directors of Cyclacel, Fitters Parent, and Fitters Sub have unanimously approved the Exchange Agreement and its amendment.
• For U.S. federal income tax purposes, the exchange is considered a taxable disposition for Fitters Parent and an acquisition for Cyclacel, with the parties intending to report it consistently with Sections 1001 and 1221 (or 1231) of the Internal Revenue Code.

Sentiment

Score: 4

Explanation: The amendment indicates a decline in Cyclacel's valuation, requiring an additional cash payment and a delay in the transaction. While the deal is proceeding, these factors suggest a less favorable position for Cyclacel than initially planned. The diversification into a new industry could be positive long-term, but the immediate implications are negative due to increased cost and delay.

Positives

• The Boards of Directors of Cyclacel, FITTERS Diversified Berhad, and FITTERS Sdn. Bhd. have unanimously approved the amended Exchange Agreement, indicating strong internal alignment.
• The amendment ensures the continuation of the strategic acquisition despite a decline in Cyclacel's valuation, demonstrating commitment to the transaction.
• The acquisition of FITTERS Sdn. Bhd. will diversify Cyclacel's business into fire safety materials, equipment, and prevention systems, potentially broadening its revenue streams beyond biopharmaceuticals.

Negatives

• Cyclacel's valuation has declined since the original agreement, necessitating an additional cash payment of USD $1,000,000 to FITTERS Diversified Berhad.
• The transaction's closing date has been extended to September 30, 2025, indicating a delay in the completion of the acquisition.
• The additional cash consideration represents an increased cost for Cyclacel to complete the acquisition.

Risks

• Conditions to the closing of the proposed transaction may not be satisfied, including failure to obtain timely stockholder approval or required regulatory clearances.
• Uncertainties exist regarding the timing of the consummation of the proposed transaction and the ability of Cyclacel and FITTERS Diversified Berhad to complete it.
• Cyclacel and FITTERS Sdn. Bhd. may face challenges in successfully integrating their businesses and achieving anticipated synergies.
• Anticipated benefits of the proposed transaction, such as revenues, expenses, earnings, financial results, growth, expansion, and tax treatment, may not be realized.
• Potential litigation related to the proposed transaction could be instituted against Cyclacel, FITTERS Sdn. Bhd., FITTERS Diversified Berhad, or their respective directors.
• Possible disruptions from the proposed transaction could harm the respective businesses of Cyclacel and FITTERS Sdn. Bhd.
• Challenges may arise in retaining, attracting, and hiring key personnel for the combined entity.
• Potential adverse reactions or changes to relationships with customers, employees, suppliers, or other parties may result from the announcement or completion of the proposed transaction.
• Business uncertainty, including changes to existing business relationships, during the pendency of the proposed transaction that could affect Cyclacel's or FITTERS Sdn. Bhd.'s financial performance.
• Certain restrictions during the pendency of the proposed transaction that may impact Cyclacel's or FITTERS Sdn. Bhd.'s ability to pursue certain business opportunities or strategic transactions.
• Legislative, regulatory, and economic developments could impact the transaction or the combined business.
• Unpredictability and severity of catastrophic events, including acts of terrorism or outbreak of war or hostilities, could affect the transaction or operations.
• Other factors as set forth in Cyclacel's periodic public filings with the SEC, including those described under the heading Risk Factors in the Company's Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The transaction is expected to close by September 30, 2025, subject to the satisfaction of closing conditions, including stockholder and regulatory approvals. Cyclacel intends to file a Form S-4 registration statement, which will include a proxy statement/prospectus, with the SEC regarding the proposed transaction.

Management Comments

• The Boards of Directors of Cyclacel, FITTERS Diversified Berhad, and Fitters Sdn. Bhd. have unanimously approved the Exchange Agreement.

Industry Context

This amendment signifies Cyclacel Pharmaceuticals' continued strategic pivot or diversification beyond its core biopharmaceutical business into the fire safety and protective equipment sector through the acquisition of FITTERS Sdn. Bhd. While Cyclacel is a clinical-stage cancer medicine developer, this move into a seemingly unrelated industry like fire safety suggests a strategy to broaden its business base, potentially for revenue diversification or asset utilization. This contrasts with typical biopharmaceutical companies that focus on drug development and commercialization, and could be seen as an attempt to stabilize or enhance overall company valuation by adding a more established, revenue-generating business, especially given the stated decline in Cyclacel's own valuation.

Stakeholder Impact

• Shareholders (Cyclacel): Will experience dilution from the issuance of 19.99% of common stock and bear the cost of the additional $1,000,000 cash payment, potentially impacting share value. The diversification into a new industry could alter the company's risk profile and long-term growth prospects.
• Shareholders (FITTERS Diversified Berhad): Will receive additional cash consideration of $1,000,000 in addition to Cyclacel shares, potentially increasing the value received for their subsidiary.
• Employees (Cyclacel & FITTERS Sdn. Bhd.): May face business uncertainty during the pendency of the transaction and potential integration challenges, including retention and attraction of key personnel.
• Customers & Suppliers (Cyclacel & FITTERS Sdn. Bhd.): Could experience changes in relationships or potential disruptions during the integration process.

Next Steps

• Cyclacel Pharmaceuticals, Inc. will pay USD $1,000,000 (or a mutually agreed amount) to FITTERS Diversified Berhad at closing.
• The transaction is subject to approval from Cyclacel stockholders and FITTERS Diversified Berhad.
• Cyclacel Pharmaceuticals, Inc. intends to file a registration statement on Form S-4, including a proxy statement/prospectus, with the SEC.
• The closing of the Exchange is expected to occur no later than three business days after the conditions are satisfied or waived, with the Final Date extended to September 30, 2025.
• Fitters Parent, if not a U.S. person, must deliver IRS Form W-8BEN-E and a Form of Tax Certificate to Cyclacel at least two business days prior to closing.

Key Dates

Recommendation

Keywords

Cyclacel Pharmaceuticals, FITTERS Diversified Berhad, FITTERS Sdn. Bhd., Exchange Agreement, Acquisition, Merger, Biopharmaceutical, Fire Safety, Corporate Transaction, SEC Filing, Form 8-K, Valuation Decline, Cash Consideration, Transaction Extension, Nasdaq, Malaysia